Terms: = Breast cancer AND uPA AND Prognosis
156 results:
1. MMP-11 expression in early luminal breast cancer: associations with clinical, MRI, pathological characteristics, and disease-free survival.
Molière S; Lodi M; Leblanc S; Gressel A; Mathelin C; Alpy F; Chenard MP; Tomasetto C
BMC Cancer; 2024 Mar; 24(1):295. PubMed ID: 38438841
[TBL] [Abstract] [Full Text] [Related]
2. Z-Endoxifen prevents aggressive mammary cancers in mice by inhibiting cell proliferation and creating a tumor suppressive microenvironment.
Lee O; Wang M; Hosseini O; Bosland MC; Muzzio M; Helenowski I; Khan SA
Biomed Pharmacother; 2023 Jun; 162():114607. PubMed ID: 37001185
[TBL] [Abstract] [Full Text] [Related]
3. Distinct expression and function of breast cancer metastasis suppressor 1 in mutant P53 glioblastoma.
Babu D; Chintal R; Panigrahi M; Phanithi PB
Cell Oncol (Dordr); 2022 Dec; 45(6):1451-1465. PubMed ID: 36284039
[TBL] [Abstract] [Full Text] [Related]
4. Effects of thiostrepton alone or in combination with selumetinib on triple-negative breast cancer metastasis.
Demirtas Korkmaz F; Dogan Turacli I; Esendagli G; Ekmekci A
Mol Biol Rep; 2022 Nov; 49(11):10387-10397. PubMed ID: 36097108
[TBL] [Abstract] [Full Text] [Related]
5.
Boissière-Michot F; Mollevi C; Baecker V; Crapez E; Jacot W
Int J Mol Med; 2022 Jun; 49(6):. PubMed ID: 35475537
[TBL] [Abstract] [Full Text] [Related]
6. [upa/PAI-1 and EPClin®: Comparison of their impact on the management of intermediate-prognosis breast cancers].
Maniez P; Osada M; Reix N; Mathelin C
Gynecol Obstet Fertil Senol; 2022 Apr; 50(4):298-306. PubMed ID: 34626849
[TBL] [Abstract] [Full Text] [Related]
7. An Activatable Polymeric Reporter for Near-Infrared Fluorescent and Photoacoustic Imaging of Invasive cancer.
Li Q; Li S; He S; Chen W; Cheng P; Zhang Y; Miao Q; Pu K
Angew Chem Int Ed Engl; 2020 Apr; 59(18):7018-7023. PubMed ID: 32124526
[TBL] [Abstract] [Full Text] [Related]
8. pH-Sensitive Shell-Core Platform Block DNA Repair Pathway To Amplify Irreversible DNA Damage of Triple Negative breast cancer.
Dong Y; Liao H; Fu H; Yu J; Guo Q; Wang Q; Duan Y
ACS Appl Mater Interfaces; 2019 Oct; 11(42):38417-38428. PubMed ID: 31556584
[TBL] [Abstract] [Full Text] [Related]
9. Impact of upa/PAI-1 and disseminated cytokeratin-positive cells in breast cancer.
Märkl B; Kazik M; Harbeck N; Jakubowicz E; Hoffmann R; Jung T; Steinfeld D; Schenkirsch G; Schlimok G; Oruzio D
BMC Cancer; 2019 Jul; 19(1):692. PubMed ID: 31307406
[TBL] [Abstract] [Full Text] [Related]
10. Stromal coexpression of upa/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.
Singer CF; Filipits M; Jahn SW; Abete L; Jakesz R; Greil R; Bauernhofer T; Kwasny W; Seifert M; Fitzal F; Kastner M; Schmitt M; Moinfar F; Gnant M
Breast; 2019 Aug; 46():101-107. PubMed ID: 31132475
[TBL] [Abstract] [Full Text] [Related]
11. EndoPredict versus upa/PAI-1 in breast cancer: Comparison of markers and association with clinicopathological parameters.
Jakubowicz E; Martin B; Hoffmann R; Kröncke T; Jung T; Steierl R; Steinfeld D; Schenkirsch G; Kriegsmann J; Märkl B
Breast J; 2019 May; 25(3):450-454. PubMed ID: 31001905
[TBL] [Abstract] [Full Text] [Related]
12. Correlation of Serum Levels of Urokinase Activation Plasminogen (upa) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive breast cancer.
Pusina S
Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
[TBL] [Abstract] [Full Text] [Related]
13. XBP1 promotes tumor invasion and is associated with poor prognosis in oral squamous cell carcinoma.
Sun Y; Jiang F; Pan Y; Chen X; Chen J; Wang Y; Zheng X; Zhang J
Oncol Rep; 2018 Aug; 40(2):988-998. PubMed ID: 29916547
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic and predictive biomarkers in breast cancer: Past, present and future.
Nicolini A; Ferrari P; Duffy MJ
Semin Cancer Biol; 2018 Oct; 52(Pt 1):56-73. PubMed ID: 28882552
[TBL] [Abstract] [Full Text] [Related]
15. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM).
Duffy MJ; Harbeck N; Nap M; Molina R; Nicolini A; Senkus E; Cardoso F
Eur J Cancer; 2017 Apr; 75():284-298. PubMed ID: 28259011
[TBL] [Abstract] [Full Text] [Related]
16. Cyr61 and YB-1 are novel interacting partners of upaR and elevate the malignancy of triple-negative breast cancer.
Huber MC; Falkenberg N; Hauck SM; Priller M; Braselmann H; Feuchtinger A; Walch A; Schmitt M; Aubele M
Oncotarget; 2016 Jul; 7(28):44062-44075. PubMed ID: 27286449
[TBL] [Abstract] [Full Text] [Related]
17. Suppressive effects of a proton beam on tumor growth and lung metastasis through the inhibition of metastatic gene expression in 4T1 orthotopic breast cancer model.
Kwon YS; Lee KS; Chun SY; Jang TJ; Nam KS
Int J Oncol; 2016 Jul; 49(1):336-42. PubMed ID: 27176787
[TBL] [Abstract] [Full Text] [Related]
18. Ulipristal Acetate Inhibits Progesterone Receptor Isoform A-Mediated Human breast cancer Proliferation and BCl2-L1 Expression.
Esber N; Le Billan F; Resche-Rigon M; Loosfelt H; Lombès M; Chabbert-Buffet N
PLoS One; 2015; 10(10):e0140795. PubMed ID: 26474308
[TBL] [Abstract] [Full Text] [Related]
19. Biomarkers in breast cancer: Where Are We and Where Are We Going?
Duffy MJ; Walsh S; McDermott EW; Crown J
Adv Clin Chem; 2015; 71():1-23. PubMed ID: 26411409
[TBL] [Abstract] [Full Text] [Related]
20. Markers of progression and invasion in short term follow up of untreated breast cancer patients.
Rabi ZA; Todorović-Raković N; Vujasinović T; Milovanović J; Nikolić-Vukosavljević D
Cancer Biomark; 2015; 15(6):745-54. PubMed ID: 26406416
[TBL] [Abstract] [Full Text] [Related]
[Next]
